- Home
- NBBK vs IMNM Comparison
NBBK vs IMNM Comparison
Compare NBBK & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- IMNM
- Stock Information
- Founded
- NBBK 1892
- IMNM 2006
- Country
- NBBK United States
- IMNM United States
- Employees
- NBBK N/A
- IMNM N/A
- Industry
- NBBK
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- NBBK
- IMNM Health Care
- Exchange
- NBBK Nasdaq
- IMNM Nasdaq
- Market Cap
- NBBK 687.7M
- IMNM 748.3M
- IPO Year
- NBBK N/A
- IMNM 2020
- Fundamental
- Price
- NBBK $18.83
- IMNM $8.89
- Analyst Decision
- NBBK Buy
- IMNM Strong Buy
- Analyst Count
- NBBK 1
- IMNM 5
- Target Price
- NBBK $22.00
- IMNM $26.40
- AVG Volume (30 Days)
- NBBK 392.5K
- IMNM 1.0M
- Earning Date
- NBBK 07-23-2025
- IMNM 08-11-2025
- Dividend Yield
- NBBK N/A
- IMNM N/A
- EPS Growth
- NBBK 421.39
- IMNM N/A
- EPS
- NBBK 1.18
- IMNM N/A
- Revenue
- NBBK $169,131,000.00
- IMNM $10,938,000.00
- Revenue This Year
- NBBK N/A
- IMNM N/A
- Revenue Next Year
- NBBK N/A
- IMNM $310.65
- P/E Ratio
- NBBK $15.96
- IMNM N/A
- Revenue Growth
- NBBK 27.71
- IMNM N/A
- 52 Week Low
- NBBK $15.08
- IMNM $5.15
- 52 Week High
- NBBK $21.05
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- NBBK 75.56
- IMNM 51.37
- Support Level
- NBBK $18.14
- IMNM $8.40
- Resistance Level
- NBBK $19.04
- IMNM $8.99
- Average True Range (ATR)
- NBBK 0.50
- IMNM 0.47
- MACD
- NBBK 0.24
- IMNM -0.05
- Stochastic Oscillator
- NBBK 98.21
- IMNM 56.20
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.